CA-ARMORY
Armory, the Continuous Deployment company empowering development teams to easily, reliably, safely, and continuously deploy software at any scale, today announced public early access to their new Continuous Deployment-as-a-Service product. Armory Continuous Deployment-as-a-Service delivers declarative deployments, across multiple environments, that support advanced strategies, so developers can focus on building great code rather than deploying it.
“We believe deploying software continuously, at any scale, should be achievable and effortless for all developers of the world, not just the likes of Google and Netflix,” said Jim Douglas, President and CEO, Armory. “It’s our vision and mission to unlock innovation through software to make software continuous, scalable, secure, and safe, so developers can improve and protect their customers’ experience with confidence and ease.”
To effectively compete in a software-defined world, development teams must ensure a stellar customer experience. Some do this by focusing on velocity, others do this by ensuring their software is both always available and reliable. Delivering on both velocity and stability has remained difficult and elusive… until now. Armory Continuous Deployment-as-a-Service plugs into any existing Software Development Lifecycle (SDLC) and can be invoked from any existing toolchain or Continuous Integration (CI) system, including Amazon CodePipeline. This allows development teams to easily leverage the power of Armory Continuous Deployment-as-a-Service when deploying to Kubernetes services like Amazon Elastic Kubernetes Service (Amazon EKS).
A single hour of downtime can cost more than $100,000 for many companies. Armory Continuous Deployment-as-a-Service prevents this type of loss, both as a standalone product for cloud-first companies — and as an extension of a leading Continuous Delivery (CD) solution — SpinnakerTM . Armory Continuous Deployment-as-a-Service provides easy-to-use, environment-specific controls to specify how much traffic is exposed to new changes and to automatically roll back if needed. This enables development teams to continuously verify a service is healthy before routing all traffic to the new version, limiting risk exposure and protecting the customer experience.
“I really like Armory Continuous Deployment-as-a-Service. It's also a fantastic extension for our Spinnaker users. I don't see anyone else doing that in the industry, which is really cool.” ~ Damian Myerscough, Software Engineer, DoorDash
Additional Resources
About Armory
Armory enables developers to continuously improve and assure their customer experience.
Software developers should be able to deploy their code effortlessly, without writing scripts, managing underlying tooling, or worrying about whether their customers are going to experience an outage. But, software deployment often is complex and full of manual process that leads to customer outages and less time spent on innovation. The bottom line, it remains disruptive, time-consuming, and unreliable.
Armory makes continuous deployment achievable and effortless, at any scale, for all developers. By providing easy-to-use continuous deployment solutions that eliminate the need to migrate away from existing tools, minimizing disruption to an existing software delivery lifecycle; developers can easily and declaratively deploy new versions alongside live versions, incrementally scale up new versions, enable manual reviews prior to scaling up, effortlessly rollback to an old version, and, manage the deployment across multiple targets and environments; continuously improving and protecting their customer experience.
Founded in 2016, Armory is funded by B Capital, Insight Partners, Crosslink Capital, Bain Capital Ventures, Mango Capital, Y Combinator, and Javelin Venture Partners.
Learn more at www.armory.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005472/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
Traxys Group and the Shareholders of Comax2 AB - the holding company of Carbomax AB - sign Share Purchase Agreement to sell 100% interests to Traxys Group12.1.2026 19:20:00 CET | Press release
Traxys S.à.r.l., Investment Aktiebolaget Spiltan and other major shareholders of Comax 2 AB – the holding company of Carbomax AB –are pleased to announce that they have signed a Share Purchase Agreement (SPA) to sell 100% interests to Traxys Group. Carbomax AB is a leading Swedish trading house and industrial operator specializing in ferroalloys, carbon products and briquettes. The transaction aims to strengthen Traxys’ presence in the Scandinavian market and support the region’s transition toward sustainable steel production. Closing of the transaction is expected to occur in the first quarter 2026 following clearance by Swedish authorities, including foreign direct investment and antitrust approvals. Carbomax serves regional steel plants and most of foundries across the Nordics. With its strategic location near Västerås harbor and integrated processing capabilities Carbomax is well-positioned to capitalize on growing demand for green steel and sustainable raw materials. Mark Kristoff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom